Biotech Israel 2005
Venue: David Intercontinental Hotel
|Event Date/Time: May 24, 2005||End Date/Time: May 26, 2005|
|Registration Date: May 19, 2005|
|Early Registration Date: May 19, 2005|
|Abstract Submission Date: Mar 15, 2005|
|Paper Submission Date: Mar 15, 2005|
It is my pleasure to invite you to participate in the Israel Bio-Tech 2005 the 4th national Conference and Exhibition of the Israeli Life Science and Technology Industry.
Israel-Biotech 2005 will be held under the auspices of the newly formed
ILSI - Israel Life Science Industry and INNI - Israel National Nanotechnology Initiative.
Israel biotech 2005 is expanding its scope to include the well-established medical device segment and emerging technologies such as Nano-Bio and Cell therapy in addition to the traditional biotech industry.
Each day will begin with a plenary presentation by a world-renowned scientist. We are looking foreword to an inspirational experience.
The organizing committee has decided to create a new format to Israel Biotech 2005. Our objective as providers of health-care solutions is to address the unmet needs in a more comprehensive manner by merging different approaches and technologies to improve the Human condition. In that light the conference will focus on four disease areas: cancer, cardiovascular diseases, CNS and Metabolic disorders.
Leading researchers from academia and industry, from Israel and abroad, will present their understanding and vision of future developments from the perspective of basic science, pharmacological interventions, device and device-drug interventions. Finally, Israeli start-ups active in this areas will present their activities. This will give participants and audience a comprehensive state-of-art and vision of such disease areas.
Special attention will be given to the financial and economic environment of the Israeli Life Science Industry through the participation of leading representatives of government and the V.C community in Israel and abroad.
I am sure that Israel Bio-Tech 2005 will be a conference especially suited to the large Israeli Life Science and Technology community. It will be an opportunity to present our achievements to the many visitors form abroad and create new contacts. Let me urge each one of you to participate in this exciting event.
Aharon Schwartz, Ph.D., Teva
Bio-Tech Israel 2005 Conference